These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1598944)

  • 1. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists.
    Falbe WJ; Bess DT; Capers CC; Haymond JD; Stahl AA
    Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944
    [No Abstract]   [Full Text] [Related]  

  • 2. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
    Oh T; Franko TG
    Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
    Berkowitz HS
    Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibiotic surveillance: the results of a clinical pharmacy intervention program.
    Capers CC; Bess DT; Branam AC; Falbe WJ; Mrochek SA; Haymond JD; Stahl AA
    Hosp Pharm; 1993 Mar; 28(3):206-10, 212. PubMed ID: 10124947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital.
    Dannenhoffer MA; Slaughter RL; Hunt SN
    Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Criteria-based DUE aids in selection of preferred agent.
    Drea EJ
    Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Documentation of clinical and cost-saving pharmacy interventions in the emergency room.
    Levy DB
    Hosp Pharm; 1993 Jul; 28(7):624-7, 630-4, 653. PubMed ID: 10127297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a pharmacy-based cost-containment program on cimetidine costs and use.
    Kong KM; Johnson WF; Anderson PO; Sato LA; Simonian RI
    Am J Hosp Pharm; 1987 Sep; 44(9):2068-73. PubMed ID: 3674045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative evaluation of cimetidine and ranitidine.
    Zimmerman TW; Schenker S
    Ration Drug Ther; 1985 Apr; 19(4):1-7. PubMed ID: 2932770
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
    Chase SL; Peterson AM; Wordell CJ
    Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of formulary restriction demonstrates significant cost savings.
    Wetmore RW; Jennings RH
    Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals.
    Segal R; Russell WL; Oh T; Ben-Joseph R
    Am J Hosp Pharm; 1993 Oct; 50(10):2077-81. PubMed ID: 8238052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of potential and real cost savings by the addition of ranitidine to total parenteral nutrition solutions.
    Pearson VE; King LM
    Hosp Pharm; 1992 Jul; 27(7):610, 613-4. PubMed ID: 10119189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.